Compare BridgeBio Pharma Inc (BBIO) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Quanta Services Inc — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Quanta Services Inc trades at $664.1 (market cap $99.18B). The key difference: Quanta Services Inc is far larger — about 6× BridgeBio Pharma Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PWR | |
|---|---|---|
Market Cap | $16.46B | $99.18B |
Sector | Health | Industrials |
52-Week High | $90.17 | $785.24 |
52-Week Low | $44.81 | $372.50 |
Enterprise Value | $18.02B | $105.14B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Quanta Services (PWR) trades at $646.70, down 1.8% with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins are thin at 3.67%. Analyst consensus is strongly bullish with a $836.80 price target, representing 29% upside potential from current levels.
PWR offers exposure to infrastructure spending tailwinds from AI data centers and grid modernization, but faces valuation concerns with a P/E of 88.7. The stock's premium multiple requires flawless execution amid aggressive capital expenditure plans. Near-term technical weakness contrasts with strong institutional support and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
